Heart, blood and circulation
442 treatments and conditions followed through the public trial records. Not medical advice. How a status is set
Treatments and conditions
| Treatment and condition | Where it stands | Trials |
|---|---|---|
| "Trained Eye" (Angiography-Guided) LM PCI for coronary artery disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| 1 Stent for coronary artery disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| 2 Stents for coronary artery disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| AAV2/8-HLP-FVIII-V3 for hemophilia a | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| AB-8939 for gata2 deficiency | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Abatacept for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Acetylcysteine for st elevation myocardial infarction | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Albipagrastim alf for febrile neutropenia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ALEMTUZUMAB + Cyclophosphamide + FLUDARABINE for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ALEMTUZUMAB + Cyclophosphamide + FLUDARABINE + Melphalan for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| allogeneic hematopoietic stem cell transplantation + Pharmacological Study + CLOFARABINE + Melphalan + Sirolimus + Tacrolimus for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Alpelisib for lymphatic abnormalities | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Amiodarone for heart arrest | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Amrecibart for atrial fibrillation | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Amrecibart for thrombosis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Amrecibart for venous thromboembolism | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ANB-010, dose 1 for hemophilia a | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ANB-010, dose 2 for hemophilia a | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ANB-010, dose 3 for hemophilia a | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Antithrombin iii human for antithrombin iii deficiency | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Apixaban for heart failure | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Apixaban for thrombosis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Arm 1: treatment with Shockwave Reducer for angina pectoris | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Aroxxen for coronary artery disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ascorbic Acid for myelodysplastic syndromes | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Asparaginase Erwinia Chrysanthemi, Recombinant-Rywn + G-CSF + ITMHA + CYTARABINE + Dexrazoxane + ETOPOSIDE + Decitabine + SORAFENIB + Mitoxantrone + ASPARAGINASE ERWINIA CHRYSANTHEMI + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Asparaginase Erwinia Chrysanthemi, Recombinant-Rywn + G-CSF + ITMHA + CYTARABINE + Dexrazoxane + ETOPOSIDE + SORAFENIB + Mitoxantrone + ASPARAGINASE ERWINIA CHRYSANTHEMI + Azacitidine + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Aspirin for purpura, thrombotic thrombocytopenic | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ASTX727 for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ATIR101 + T-cell depleted HSCT from a related, haploidentical donor for myelodysplastic syndromes | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ATO + Ascorbic acid for myelodysplastic syndromes | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Atorvastatin for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Atorvastatin for myocardial infarction | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Autoinjector + EVOLOCUMAB for coronary artery disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Autologous testicular tissue transplantation of prepubertal frozen testicular tissue for hematologic diseases | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Avacopan for vasculitis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Azacitidine for anemia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Azacitidine for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Azacitidine for thrombocytopenia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Azacitidine + Ascorbic Acid for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Azacitidine + Ascorbic Acid for myeloproliferative disorders | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Azacitidine + ENASIDENIB MESYLATE for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Azacitidine + Venetoclax + Mobinitinib for myelodysplastic syndromes | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| AZD3632 for myelodysplastic syndromes | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| AZD3632 + Posaconazole for myelodysplastic syndromes | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Baxdrostat for hypertension | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| Benralizumab for hypereosinophilic syndrome | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Benserazide Only Product for anemia, sickle cell | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Benserazide Only Product for beta-thalassemia | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Bezuclastinib for myeloproliferative disorders | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Biospecimen Collection + Bone Marrow Aspiration + Olaparib for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| BiOSS LIM C for coronary artery disease | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| BiOSS LIM C for coronary stenosis | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| BiVACOR TAH System for heart failure | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| BMS-986470 for anemia, sickle cell | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| BMS-986470 + Famotidine + PANTOPRAZOLE for anemia, sickle cell | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| BMS-986470 + Placebo for anemia, sickle cell | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| BPA prophylaxis + Factor (FVIII or FIX) prophylaxis + FITUSIRAN for hemophilia a | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Bread with added beta-glucans for hypertension | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Brentuximab vedotin for hematologic diseases | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CagriSema for hypertension | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Calf Plantar flexion + Dietary nitrate for peripheral arterial disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Canakinumab for atherosclerosis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Canakinumab for myocardial infarction | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cardiovalve TR valve replacement System for tricuspid valve insufficiency | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cardiovascular Polypill for myocardial infarction | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cardiovascular Polypill (Valsartan, Atorvastatin, Aspirin) + Colchicine 0.5 mg for atherosclerosis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cardiovascular Polypill (Valsartan, Atorvastatin, Aspirin) + Colchicine-placebo 0.5 mg for atherosclerosis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Carvedilol for heart failure | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cenvacibart for atrial fibrillation | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Cenvacibart for thrombosis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Cenvacibart for venous thromboembolism | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cholecalciferol for myocardial infarction | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CID-103 for purpura | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CIPROFLOXACIN + Ceftazidime for febrile neutropenia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Clazakizumab for atherosclerosis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Clazakizumab for hypertension | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CliniMACS + G-CSF + HPC,A Infusion + RITUXIMAB + BLINATUMOMAB + Cyclophosphamide + THIOTEPA + LAPINE T-LYMPHOCYTE IMMUNE GLOBULIN + Mesna + FLUDARABINE + Melphalan + Sirolimus + Tacrolimus for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CliniMacs TCR alpha-beta-Biotin system for myelodysplastic syndromes | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Clopidogrel for acute coronary syndrome | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Clopidogrel for angina, stable | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Clopidogrel for myocardial infarction | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Clotting factor concentrates (CFC) or bypassing agents (BPA) + EMICIZUMAB + FITUSIRAN + ANTITHROMBIN III HUMAN for hemophilia a | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Clotting factor concentrates (CFC) or bypassing agents (BPA) + FITUSIRAN + ANTITHROMBIN III HUMAN for hemophilia a | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Colchicine for acute coronary syndrome | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Colchicine for coronary artery disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Colchicine for coronary disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Colchicine for heart failure | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Colchicine for myocardial infarction | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Colchicine for myocarditis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Colchicine 0.5 mg for atherosclerosis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Colchicine 0.5 mg for coronary disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Colchicine 0.5 mg for heart diseases | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Colchicine 0.5 mg + Usual Care Group for atherosclerosis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Colchicine-placebo 0.5 mg + Usual Care Group for atherosclerosis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Combined antioxidant therapy for myocardial reperfusion injury | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Combined antioxidant therapy for st elevation myocardial infarction | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Control for hypertension | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Coronary Sinus Reducer for angina pectoris | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Coronary Sinus Reducer for angina, stable | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Coronary Sinus Reducer for coronary artery disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Coronary Sinus Reducer for microvascular angina | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| CREADY (Cognitive-Remediation of Executive and Adaptive Deficits in Youth) for anemia, sickle cell | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Crizanlizumab for anemia, sickle cell | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CSL222 (AAV5-hFIXco-Padua) for hemophilia b | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CSL222 (Adeno-associated viral vector serotype 5 [AAV5]-hFIXco-Padua) for hemophilia b | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cyclophosphamide for anemia, refractory, with excess of blasts | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cyclophosphamide for myelodysplastic syndromes | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CYTARABINE + Cladribine + Azacitidine + Venetoclax for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Danicopan for hemoglobinuria, paroxysmal | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Dapagliflozin for heart failure | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Dapagliflozin + Empagliflozin for heart failure, systolic | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Dapagliflozin propanediol for heart failure, systolic | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Darbepoetin alfa + canakinumab for myelodysplastic syndromes | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| DCD Heart Transplantation Using NRP for heart failure | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Decitabine + ARSENIC TRIOXIDE for myelodysplastic syndromes | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Decitabine + QUIZARTINIB + Venetoclax for myelodysplastic syndromes | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| DIAG723 for telangiectasia, hereditary hemorrhagic | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Direct oral anticoagulant for acute coronary syndrome | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Direct oral anticoagulant for embolism | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Direct oral anticoagulant for heart failure | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Direct oral anticoagulant for st elevation myocardial infarction | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Donor Leukocyte Infusion (DLI) + INTERFERON GAMMA-1B for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Donor mobilized PBSC infusion + G-CSF + RITUXIMAB + Cyclophosphamide + MP + FLUDARABINE for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Donor mobilized PBSC infusion + G-CSF + Total Body Irradiation (TBI) (Plan 1) + RITUXIMAB + Cyclophosphamide + MP + FLUDARABINE for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Doxycycline for lymphatic abnormalities | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| EA-230 90mg/kg/hour for coronary artery disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Echocardiography + Electrocardiogram (ECG) + DEFERIPRONE + Deferoxamine + Deferasirox for anemia, sickle cell | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Echocardiography + Electrocardiogram (ECG) + DEFERIPRONE + Deferoxamine + Deferasirox for arrhythmias, cardiac | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Echocardiography + Electrocardiogram (ECG) + DEFERIPRONE + Deferoxamine + Deferasirox for cardiomyopathies | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| EDG-15400 25 mg for heart failure | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| EDG-15400 50 mg for heart failure | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| EDIT-301 for anemia, sickle cell | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Edwards EVOQUE System for heart failure | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Edwards EVOQUE System for tricuspid valve insufficiency | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Edwards EWJ-202 Transcatheter Tricuspid Valve Replacement System for tricuspid valve insufficiency | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| efanesoctocog alfa (BIVV001) for hemophilia a | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Electronic Cigarette and behavioural change support. for cardiovascular diseases | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Eloralintide for cardiovascular diseases | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Elritercept for anemia | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Elritercept for myelodysplastic syndromes | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Empagliflozin for cardiomyopathy, hypertrophic | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Empagliflozin for heart defects, congenital | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Empagliflozin for heart failure | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 13 |
| Empagliflozin for heart failure, diastolic | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Empagliflozin for ventricular dysfunction, right | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Enavogliflozin for tricuspid valve insufficiency | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Endocalyx Pro for hypertension | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ENDS (Vaporizer/e-cig) and smoking cessation counseling for cardiovascular diseases | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Enlicitide Decanoate for arteriosclerosis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Essential Pro Paclitaxel Drug-Eluting Balloon for coronary artery disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Evolocumab for coronary artery disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Evolocumab for coronary disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Evolocumab for non-st elevated myocardial infarction | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Evolocumab for st elevation myocardial infarction | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Exagamglogene autotemcel for anemia, sickle cell | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 5 |
| Exagamglogene autotemcel for beta-thalassemia | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Exercise for hypertension | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Exerenibart for beta-thalassemia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Exploratory test group for hypertension | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ferric derisomaltose for heart failure | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fidanacogene Elaparvovec for hemophilia a | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Fidanacogene Elaparvovec for hemophilia b | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| Finerenone for atrial fibrillation | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fisetin for intermittent claudication | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fitusiran for hemophilia a | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 4 |
| Fitusiran for hemophilia b | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Fixed-Dose Combination Strategy for hypertension | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Flecainide for heart arrest | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Flecainide for mitral valve prolapse | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| FOLFIRI + FOLFOX6/FOLFOX7 + S241656 + PANITUMUMAB + Cetuximab for histiocytosis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Food Security Screening & Referral Program for cardiovascular diseases | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| G-CSF + ITMHA + CYTARABINE + Dexrazoxane + ETOPOSIDE + Decitabine + Mitoxantrone + ASPARAGINASE ERWINIA CHRYSANTHEMI + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| G-CSF + ITMHA + CYTARABINE + Dexrazoxane + ETOPOSIDE + Decitabine + Mitoxantrone + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| G-CSF + ITMHA + CYTARABINE + Dexrazoxane + ETOPOSIDE + Decitabine + SORAFENIB + Mitoxantrone + ASPARAGINASE ERWINIA CHRYSANTHEMI + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| G-CSF + ITMHA + CYTARABINE + Dexrazoxane + ETOPOSIDE + Decitabine + SORAFENIB + Mitoxantrone + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| G-CSF + ITMHA + CYTARABINE + Dexrazoxane + ETOPOSIDE + Mitoxantrone + ASPARAGINASE ERWINIA CHRYSANTHEMI + Azacitidine + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| G-CSF + ITMHA + CYTARABINE + Dexrazoxane + ETOPOSIDE + Mitoxantrone + Azacitidine + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| G-CSF + ITMHA + CYTARABINE + Dexrazoxane + ETOPOSIDE + SORAFENIB + Mitoxantrone + ASPARAGINASE ERWINIA CHRYSANTHEMI + Azacitidine + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| G-CSF + ITMHA + CYTARABINE + Dexrazoxane + ETOPOSIDE + SORAFENIB + Mitoxantrone + Azacitidine + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| G-CSF + ITMHA + Stem Cell Transplant + CYTARABINE + Dexrazoxane + ETOPOSIDE + Decitabine + SORAFENIB + Mitoxantrone + ASPARAGINASE ERWINIA CHRYSANTHEMI + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| G-CSF + ITMHA + Stem Cell Transplant + CYTARABINE + Dexrazoxane + ETOPOSIDE + SORAFENIB + Mitoxantrone + ASPARAGINASE ERWINIA CHRYSANTHEMI + Azacitidine + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Genicular artery embolization (GAE) for arterial occlusive diseases | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Givinostat for primary myelofibrosis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Givinostat for thrombocythemia, essential | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Goflikicept for pericarditis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Granulocyte Colony-Stimulating Factor (G-CSF) + MGTA 456 Infusion + Busulfan + FLUDARABINE + Melphalan + Mycophenolate Mofetil Hydrochloride for anemia, refractory, with excess of blasts | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Granulocyte Colony-Stimulating Factor (G-CSF) + MGTA 456 Infusion + Total Body Irradiation (TBI) + Cyclophosphamide + FLUDARABINE + Mycophenolate Mofetil Hydrochloride + Tacrolimus for anemia, refractory, with excess of blasts | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| GVHD prophylaxis regimen + RIC regimen for anemia, sickle cell | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| GVHD prophylaxis regimen + RIC regimen for bone marrow failure disorders | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Heart to Heart Yoga for heart failure | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Hematopoietic stem-cell transplantation for myelodysplastic syndromes | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| HiCM-188 therapy for heart failure | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| High dose CABG/LVAD+iPSC-CMs for heart failure | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| High dose Jia Shen Tablet for heart failure | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| High Dose LX2006 + Low dose LX2006 + Mid Dose LX2006 for cardiomyopathies | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| High-resistance inspiratory muscle strength training for hypertension | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| hiPSC-CM therapy for cardiomyopathy, dilated | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| hiPSC-CM therapy for heart failure | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| HMB-002 (Part A) for von willebrand disease, type 3 | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| HMB-002 (Part B) for von willebrand disease, type 3 | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| HMB-002 with Concomitant Factor Concentrate (Part C) (Not Applicable in US) for von willebrand disease, type 3 | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Hydroxycarbamide for anemia, sickle cell | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Hyperpolarized 13C-pyruvate for heart failure | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| IBI3016 for hypertension | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ibuprofen for ductus arteriosus, patent | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| iCM012 solution 2 mg/mL for reperfusion injury | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Iloprost for vaso-occlusive crises | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Imatinib Mesylate for hypereosinophilic syndrome | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ime for hypertension | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ime for prehypertension | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Immediate HSCT Group for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Impella 5.5 for shock, cardiogenic | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Inclisiran for acute coronary syndrome | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Inclisiran for non-st elevated myocardial infarction | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Inclisiran for st elevation myocardial infarction | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Infliximab for aneurysm | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Infliximab for vasculitis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Innoventric Unica™ System for tricuspid valve insufficiency | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Inspiratory muscle strength training for hypertension | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Inspiratory muscle strength training for prehypertension | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Inspiratory muscle training (IMT) for hypertension | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Intensified medical follow-up and glucose-lowering drugs for coronary artery disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Intrepid™ TTVR System for tricuspid valve insufficiency | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Iron sucrose for anemia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Isatuximab for anemia, aplastic | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ketoprofen for lymphedema | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| L-PSGB first for tachycardia, ventricular | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| L-PSGB first for ventricular fibrillation | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Laboratory Biomarker Analysis + CYTARABINE + ASPARAGINASE ERWINIA CHRYSANTHEMI + ASPARAGINASE + Mitoxantrone Hydrochloride for myelodysplastic syndromes | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Laboratory Biomarker Analysis + CYTARABINE + ASPARAGINASE ERWINIA CHRYSANTHEMI + ASPARAGINASE + Mitoxantrone Hydrochloride for myeloproliferative disorders | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Laboratory Biomarker Analysis + CYTARABINE + ETOPOSIDE + THIOGUANINE + Daunorubicin Hydrochloride for myelodysplastic syndromes | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Laboratory Biomarker Analysis + CYTARABINE + ETOPOSIDE + THIOGUANINE + Daunorubicin Hydrochloride for myeloproliferative disorders | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Laplace TTVR System for tricuspid valve insufficiency | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Left main stenting with intravascular lithotripsy for atherosclerosis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Left main stenting with intravascular lithotripsy for coronary artery disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Lenalidomide for erdheim-chester disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Lepodisiran for atherosclerosis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Lepodisiran Sodium for atherosclerosis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Lorundrostat for hypertension | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| Lorundrostat 25mg+SGLT2i QD, Washout, Placebo+SGLT2i QD for hypertension | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| low dose CABG+iPSC-CMs for heart failure | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Low dose Jia Shen Tablet for heart failure | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Luspatercept for anemia | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| Luspatercept for myelodysplastic syndromes | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Luspatercept for primary myelofibrosis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Lusutrombopag combined with recombinant human thrombopoietin for thrombocytopenia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| LuxValve PLlus for tricuspid valve insufficiency | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Mandibular advancement Device for essential hypertension | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Mandibular advancement Device for heart failure | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Mandibular advancement Device for hypertension | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Maridebart Cafraglutide for atherosclerosis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Marstacimab for hemophilia a | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Marstacimab for hemophilia b | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Medical or interventional therapy for rhythm control in atrial fibrillation (antiarrhythmic drugs, ablation, electric cardio version) for atrial fibrillation | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Medtronic Intrepid™ Transcatheter Tricuspid Valve Replacement (TTVR) System for tricuspid valve insufficiency | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Metformin ER for intermittent claudication | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Metformin hydrochloride for heart failure | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Midodrine for hypotension | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Mitapivat for anemia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| MitraClip System for heart failure | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| MitraClip System for mitral valve insufficiency | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Mobilized CD34-selected Peripheral Blood Stem Cell graft for anemia, refractory, with excess of blasts | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Mobinitinib for myelodysplastic syndromes | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Momelotinib for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Muvalaplin for atherosclerosis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Narrative Intervention for Chronic Illness-Heart Failure for heart failure | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Navitoclax for primary myelofibrosis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Neovasc Reducer for angina pectoris | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Nevibolol for microvascular angina | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Nicotine-Free Electronic Cigarette and behavioural change support. for cardiovascular diseases | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| NightWare for cardiovascular diseases | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Nintedanib for telangiectasia, hereditary hemorrhagic | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Nk-dli for myelodysplastic syndromes | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| NTLA-2001 for cardiomyopathies | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| obicetrapib 10 mg + ezetimibe 10 mg FDC daily for coronary artery disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Orforglipron for cardiovascular diseases | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Orforglipron for hypertension | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Pci for acute coronary syndrome | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Peginterferon α-2b injection for thrombocythemia, essential | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Pelabresib for primary myelofibrosis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Peripheral Blood Hematopoietic Cell Transplantation (HCT) + Total body irradiation (TBI) + Cyclophosphamide + Busulfan + FLUDARABINE + FILGRASTIM + Mycophenolate Mofetil Hydrochloride + Sirolimus for myelodysplastic syndromes | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Peripheral Blood Hematopoietic Cell Transplantation (HCT) + Total body irradiation (TBI) + Cyclophosphamide + Busulfan + FLUDARABINE + FILGRASTIM + Mycophenolate Mofetil Hydrochloride + Sirolimus for primary myelofibrosis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Peripheral Blood Stem Cell Transplantation + Hematopoietic Cell Transplantation + Laboratory Biomarker Analysis + Quality-of-Life Assessment + FLUDARABINE PHOSPHATE + Cyclophosphamide + Mycophenolate Mofetil + Busulfan + Tacrolimus for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| pharmacogenetic algorithm for atrial fibrillation | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Phase 1 Dose Level 1 + Phase 1 Dose Level 2 + Phase 1 Dose Level 3 for anemia, refractory, with excess of blasts | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Phase 1 Dose Level 1 + Phase 1 Dose Level 2 + Phase 1 Dose Level 3 for congenital bone marrow failure syndromes | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Phase 1 Dose Level 1 + Phase 1 Dose Level 2 + Phase 1 Dose Level 3 for hemoglobinopathies | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Phase 2 Established Dose from prior study, NCT03810196 for anemia, refractory, with excess of blasts | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Phase 2 Established Dose from prior study, NCT03810196 for congenital bone marrow failure syndromes | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Phase 2 Established Dose from prior study, NCT03810196 for hemoglobinopathies | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Phase 2 Maximum Tolerated Dose determined in Phase 1 for anemia, refractory, with excess of blasts | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Phase 2 Maximum Tolerated Dose determined in Phase 1 for congenital bone marrow failure syndromes | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Phase 2 Maximum Tolerated Dose determined in Phase 1 for hemoglobinopathies | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Pirfenidoneone for lymphedema | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo + Empagliflozin for heart failure | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Placebo + Lorundrostat for hypertension | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Placebo + Orforglipron for hypertension | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo for Oral Azacitidine for anemia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo for Oral Azacitidine for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo for Oral Azacitidine for thrombocytopenia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo QD + SGLT2i QD, Washout, Lorundrostat 25mg+SGLT2i QD for hypertension | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Polycap for atherosclerosis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| PolyCore (Polydextrin, L-Carnitine, D-xylitol) for heart failure | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| PolyPill for cardiovascular diseases | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| PolyPill for heart diseases | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| PolyPill for hypertension | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| PolyPill for non-st elevated myocardial infarction | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| PolyPill for st elevation myocardial infarction | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Polypill: Red Heart Pill for cardiovascular diseases | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Pozelimab + cemdisiran for hemoglobinuria, paroxysmal | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Prasugrel for acute coronary syndrome | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Prasugrel or Ticagrelor for acute coronary syndrome | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Prasugrel or Ticagrelor for atrial fibrillation | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Pravastatin (drug) for lymphedema | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Prophylactic Intervention for Relapse Prevention Post-Allogeneic Transplantation for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Proton Total Marrow Irradiation for anemia, refractory, with excess of blasts | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Qidan Xiaoke Granules + Standard Medical Therapy for coronary artery disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ranolazine for heart failure | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ranolazine for ventricular dysfunction, right | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Recombinant Human Thymosin Beta 4 Injection (NL005) for anterior wall myocardial infarction | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Recombinant Human Thymosin Beta 4 Injection (NL005) for st elevation myocardial infarction | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Recombinant varicella zoster virus glycoprotein e antigen for cardiovascular diseases | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Recombinant varicella zoster virus glycoprotein e antigen for myocardial infarction | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Red Heart Pill 2b (Polypill) for cardiovascular diseases | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| reduced-dose conditioning regimen containing TBI in hematopoietic stem cell transplantation treating elderly patients with aplastic anemia for anemia, aplastic | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Regadenoson for coronary artery disease | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Retatrutide for cardiovascular diseases | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Retatrutide for coronary artery disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Retatrutide for peripheral arterial disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| RITUXIMAB + Cyclophosphamide + MP + Busulfan + FLUDARABINE for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Rivaroxaban for venous thromboembolism | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Rivogenlecleucel + rimiducid for anemia, aplastic | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Rivogenlecleucel + rimiducid for cytopenia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Rivogenlecleucel + rimiducid for myelodysplastic syndromes | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Romiplostim for anemia, aplastic | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Romiplostim for anemia, refractory, with excess of blasts | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ROPEGINTERFERON ALFA-2B for thrombocythemia, essential | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Rosuvastatin for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| RP-A501 for cardiomyopathy, hypertrophic | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| RP-A501 for hypertrophy, left ventricular | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ruxolitinib for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ruxolitinib + NAVITOCLAX for primary myelofibrosis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ruxoprubart for hemoglobinuria, paroxysmal | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| S241656 for histiocytosis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| S241656 + PEMBROLIZUMAB for histiocytosis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| S241656 + Trametinib for histiocytosis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Sacubitril-valsartan for heart failure | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| SAL0140 for hypertension | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Selinexor for primary myelofibrosis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Selnoflast for atherosclerosis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Semaglutide for atherosclerosis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Semaglutide for atrial fibrillation | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Silver diammine fluoride for heart arrest | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Sirolimus for arteriovenous malformations | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Sodium zirconium cyclosilicate for heart failure | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Sonrotoclax for myelodysplastic syndromes | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Sonrotoclax for myelodysplastic-myeloproliferative diseases | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Sonrotoclax + Azacitidine for myelodysplastic syndromes | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Sonrotoclax + Azacitidine for myelodysplastic-myeloproliferative diseases | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Sonrotoclax + Posaconazole + Azacitidine for myelodysplastic syndromes | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Sonrotoclax + Posaconazole + Azacitidine for myelodysplastic-myeloproliferative diseases | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| SPK-8011QQ for hemophilia a | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| SR604 for factor vii deficiency | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| SR604 for hemophilia a | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| SR604 for hemophilia b | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| SR604 for von willebrand diseases | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Standard of Care (SOC) for lymphedema | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Stem Cell Infusion + Total Body Irradiation + Cyclophosphamide + Mycophenolate Mofetil + TREOSULFAN + FLUDARABINE + Tacrolimus for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tai Chi (CHI) for hypertension | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tai Chi (CHI) for prehypertension | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tasquinimod for primary myelofibrosis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| TASQUINIMOD + Ruxolitinib for primary myelofibrosis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| TCRα/β+ and CD19+ depleted haploidentical stem cell transplantation for anemia, sickle cell | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tenecteplase for st elevation myocardial infarction | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tertinat for atherosclerosis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tertinat for coronary artery disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Test group for hypertension | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Thiamine Mononitrate 300 mg for heart failure | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| thrombopoietin receptor agonist (TPO-RA) + Cyclosporine + ROMIPLOSTIM for anemia, aplastic | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ticagrelor for acute coronary syndrome | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 19 |
| Ticagrelor for angina, stable | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ticagrelor for angina, unstable | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Ticagrelor for coronary artery disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 7 |
| Ticagrelor for myocardial infarction | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ticagrelor for non-st elevated myocardial infarction | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ticagrelor for st elevation myocardial infarction | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Ticagrelor + Aspirin for acute coronary syndrome | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ticagrelor + placebo for non-st elevated myocardial infarction | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ticagrelor + placebo for st elevation myocardial infarction | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tirzepatide for heart failure, systolic | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tirzepatide for hypertension | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| TNX-103 for heart failure | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| TOCOPHEROL + Pentoxifylline for lymphedema | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Topaz TTVR System for tricuspid valve insufficiency | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Total-Body Irradiation + Umbilical Cord Blood Transplantation + Cyclophosphamide + DILANUBICEL + FLUDARABINE for anemia, refractory, with excess of blasts | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Total-Body Irradiation + Umbilical Cord Blood Transplantation + Cyclophosphamide + THIOTEPA + DILANUBICEL + FLUDARABINE for anemia, refractory, with excess of blasts | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Trametinib + DABRAFENIB for erdheim-chester disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tranexamic acid for anemia | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Transcatheter PDA Coil for ductus arteriosus, patent | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Transcatheter tricuspid valve edge-to-edge repair for heart failure | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Transcatheter tricuspid valve edge-to-edge repair for tricuspid valve insufficiency | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Transcatheter Tricuspid Valve Intervention for tricuspid valve insufficiency | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Transcatheter tricuspid valve replacement for tricuspid valve insufficiency | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 6 |
| Transcatheter Tricuspid Valve Replacement (TTVR) with Laplace TTVR System for tricuspid valve insufficiency | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Transcatheter Tricuspid Valve Replacement (TTVR) with VDyne TriNova System for tricuspid valve insufficiency | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Transcatheter Tricuspid Valved Stent Graft for tricuspid valve insufficiency | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Transvenous Tricuspid Valve System implantation + OMT for tricuspid valve insufficiency | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tretinoin for thrombocytopenia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| TRiCares Topaz TTVR System for tricuspid valve insufficiency | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tricuspid Valve Replacement System for tricuspid valve insufficiency | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tricuspid Valve Replacement System via jugular vein for tricuspid valve insufficiency | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| TricValve System for heart failure | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| trigagrelor for acute coronary syndrome | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Triple oral lipid lowering treatment for acute coronary syndrome | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| TruGamma System for tricuspid valve insufficiency | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ULIXERTINIB + Ruxolitinib for primary myelofibrosis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Unmanipulated Bone Marrow Graft with Cyclophosphamide + Cyclophosphamide for anemia, refractory, with excess of blasts | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Valsartan for heart failure | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| VDyne Transcatheter Tricuspid Valve Replacement System for tricuspid valve insufficiency | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Venetoclax + AB-8939 for gata2 deficiency | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Venetoclax + FLUDARABINE for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Venous Excess Ultrasound (VEXUS)-Guided Management for hyperemia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Vericiguat for heart failure | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| VERVE-102 for atherosclerosis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| VERVE-102 for coronary artery disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| VERVE-102 for myocardial infarction | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Very-short DAPT less than 1 month after PCI for acute coronary syndrome | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Very-short DAPT less than 1 month after PCI for coronary artery disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Vicadrostat for hypertension | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| vicadrostat / empagliflozin combination 1 for heart failure | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Vitamin C (ascorbic acid) for cytopenia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Vitamin C (ascorbic acid) for myelodysplastic syndromes | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| YMI024 for coronary artery disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Zemocimig for hemophilia a | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ziltivekimab for atherosclerosis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Ziltivekimab for coronary artery disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ziltivekimab for myocardial infarction | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Zotarolimus-eluting stent (Endeavor Resolute) for coronary artery disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Zovegalisib for klippel-trenaunay-weber syndrome | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Zovegalisib for lymphatic abnormalities | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Zovegalisib for vascular malformations | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |